氨磷汀联合吉西他滨与顺铂方案治疗晚期乳腺癌的临床研究  

Amifostine combined with gemcitabine and cisplatin in the treatment of advanced breast cancer

作　　者：姜敏[1] 曾越灿[1] 迟峰[1] 吴荣[1] 

机构地区：[1]中国医科大学附属盛京医院肿瘤科,沈阳110022

出　　处：《实用药物与临床》2016年第6期683-687,共5页Practical Pharmacy and Clinical Remedies

基　　金：国家自然基金资助项目(81201803)

摘　　要：目的观察分析氨磷汀联合吉西他滨与顺铂治疗晚期乳腺癌的疗效和安全性。方法选取我院经病理确诊的52例晚期乳腺癌患者,随机分为试验组及对照组。试验组29例,应用氨磷汀500 mg/m^2,化疗开始前30 min静脉滴注;吉西他滨1 000 mg/m^2静点,第1、8天;顺铂30 mg/m^2避光静点,第1~3天。对照组23例,应用吉西他滨联合顺铂,剂量及用法同试验组。两组均以3周为1个周期。结果 52例均纳入分析,试验组、对照组的有效率分别为37.9%、47.8%,疾病控制率为70.3%、78.2%,两组比较差异无统计学意义(P>0.05)。与对照组比较,试验组骨髓抑制及周围神经毒性发生率明显降低,头晕的发生率升高,而两组肝肾功能损伤、恶心呕吐等例数比较差异无统计学意义。结论氨磷汀联合吉西他滨与顺铂治疗晚期乳腺癌,可减轻骨髓抑制及周围神经毒性,对治疗效果无影响。Objective To assess and analyze the efficacy and safety of amifostine combined with gemcitabine and cisplatin in the treatment of advanced breast cancer.Methods Fifty-two patients with advanced breast cancer were randomly divided into two groups.Trail group（n= 29） was treated with amifostine 500 mg/m^2 at 30 min before chemotherapy,gemcitabine 1 000 mg/m^2 on d 1 and d 8 and DDP 30 mg/m^2 on d1～3.Control group（n=23） was applied with gemcitabine and cisplatin of the same dose as trail group.All the patients were treated for 3 weeks as a cycle.Results All the patients（n=52） were included for analysis.The response rates were 37.9%and 47.8%in trail group and control group,and the overall disease control rates were 70.3%and 78.2%,respectively.There was no significant difference between the two groups.In amifostine group,bone marrow injury was milder and the incidence of neurotoxity was lower than control group,while the incidence of dizziness was higher.There was no significant difference in the in—cidence of hepatic function,renal function fatigue and so on.Conclusion Amifostine combined with gemcitabine and cisplatin in the treatment of advanced breast cancer can attenuate the adverse effect of chemotherapy-bone marrow injury and neurotoxity,without affecting the efficacy.

关 键 词：氨磷汀 吉西他滨 顺铂 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]